Compounds > (1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum (ii)
Page last updated: 2024-12-08
(1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum (ii)
Description
(1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum (II), also known as **Satraplatin**, is a platinum-based anticancer drug.
**Here's why it's important for research:**
* **Potential for overcoming resistance:** Satraplatin is a promising drug for treating cancers that have become resistant to traditional platinum-based chemotherapy like cisplatin. This resistance often occurs because cancer cells develop mechanisms to pump cisplatin out or to inactivate it. Satraplatin's different chemical structure may bypass these resistance mechanisms.
* **Oral administration:** Unlike cisplatin, which must be administered intravenously, satraplatin can be taken orally. This makes it more convenient for patients and potentially improves their quality of life.
* **Wider range of cancers:** Satraplatin has shown activity against a broader range of cancers than cisplatin, including prostate cancer, ovarian cancer, and lung cancer.
* **Targeted drug delivery:** Satraplatin has been investigated for targeted drug delivery systems, which could potentially improve its efficacy and reduce side effects.
**Research on Satraplatin focuses on:**
* **Understanding its mechanism of action:** How does it kill cancer cells?
* **Optimizing its efficacy:** How can we make it work better?
* **Developing new formulations:** Exploring new ways to administer satraplatin, such as nanocarriers.
* **Investigating its potential for combination therapy:** Can it be combined with other drugs to enhance its effectiveness?
**Despite showing promise, satraplatin has not yet been approved by the FDA for widespread clinical use.** This is due to concerns about its safety and efficacy in clinical trials. However, research continues to explore its potential as a treatment for various cancers.
**It is important to note that this information is for educational purposes only and should not be taken as medical advice.**
(1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum (II): RN given refers to (SP-4-2); structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 147233 |
| MeSH ID | M0209896 |
Synonyms (7)
| Synonym |
|---|
| 1,2-bdhed-pt |
| meso-(1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum(ii) |
| platinum, dichloro(4,4'-(1,2-diamino-1,2-ethanediyl)bis(3,5-dichlorophenol)-n,n')-, (sp-4-2)- |
| (1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum (ii) |
| 117773-99-6 |
| 3,5-dichloro-4-[1,2-diamino-2-(2,6-dichloro-4-hydroxyphenyl)ethyl]phenol;platinum(2+);dichloride |
| 3,5-dichloro-4-[1,2-diamino-2-(2,6-dichloro-4-hydroxyphenyl)ethyl]phenol;dichloroplatinum |
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.42
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.42 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.21 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |